- Open
- 0.12
- High
- 0.12
- Low
- 0.12
- Close
- 0.12
- Change
- -0.01 (-8.33%)
- Volume
- 2,801,829
| 24 Aug 2026 | 13:36:34 | Appointment of Administrators & Nomad Resignation |
| 21 Aug 2026 | 07:00:03 | Notice of intention to appoint Administrators |
| 12 Aug 2026 | 07:00:04 | Loan and Related Party Transaction |
| 31 Jul 2026 | 16:20:19 | Update |
| 9 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 7 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Trellus Health plc provides resilience-driven health solutions for the management of chronic conditions, focusing primarily on inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis. The company utilizes its proprietary technology platform, Trellus Elevate®, to deliver personalized, condition-agnostic programs that enhance patient engagement, improve treatment adherence, and reduce healthcare costs. Trellus Health partners with pharmaceutical companies, clinical trial organizations, large employers, and health plans to commercialize its digital chronic condition management solutions, which are based on the scientifically validated GRITT™ methodology developed in collaboration with the Mount Sinai IBD Center.
| 24 Aug 2026 | 13:36:34 | Appointment of Administrators & Nomad Resignation |
| 21 Aug 2026 | 07:00:03 | Notice of intention to appoint Administrators |
| 12 Aug 2026 | 07:00:04 | Loan and Related Party Transaction |
| 31 Jul 2026 | 16:20:19 | Update |
| 9 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 7 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Trellus Health plc provides resilience-driven health solutions for the management of chronic conditions, focusing primarily on inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis. The company utilizes its proprietary technology platform, Trellus Elevate®, to deliver personalized, condition-agnostic programs that enhance patient engagement, improve treatment adherence, and reduce healthcare costs. Trellus Health partners with pharmaceutical companies, clinical trial organizations, large employers, and health plans to commercialize its digital chronic condition management solutions, which are based on the scientifically validated GRITT™ methodology developed in collaboration with the Mount Sinai IBD Center.
| 30 Jun 2026 | 18:30:00 | Delay to Publication of Annual Report and Accounts |
| 28 Apr 2026 |
| AIM movers: IQE gets cash injection and Scancell fast tracked |
| 13 Apr 2026 | AIM movers: Mothercare suffering and Trellus Health renews Pfizer licence |
| 13 Apr 2026 | Trellus Health shares jump 39% on Pfizer deal renewal |
| 22 Feb 2026 | AIM weekly movers: Trellus Health rebounds |
| 19 Feb 2026 | AIM movers: Checkit ahead of expectations and ex-dividends |
| 18 Feb 2026 | AIM movers: Trellus Health renews contract and Roadside Real Estate fundraising |
| 30 Jun 2026 | 18:30:00 | Delay to Publication of Annual Report and Accounts |
| 28 Apr 2026 |
| AIM movers: IQE gets cash injection and Scancell fast tracked |
| 13 Apr 2026 | AIM movers: Mothercare suffering and Trellus Health renews Pfizer licence |
| 13 Apr 2026 | Trellus Health shares jump 39% on Pfizer deal renewal |
| 22 Feb 2026 | AIM weekly movers: Trellus Health rebounds |
| 19 Feb 2026 | AIM movers: Checkit ahead of expectations and ex-dividends |
| 18 Feb 2026 | AIM movers: Trellus Health renews contract and Roadside Real Estate fundraising |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £9m | -0.7% | |
| £5m | -0.8% | |
| £3m | -0.6% | |
| £3m | -0.9% | |
| £2m | -0.1% | |
TRLSTrellus Health plc | £516k | -0.9% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £9m | -0.7% | |
| £5m | -0.8% | |
| £3m | -0.6% | |
| £3m | -0.9% | |
| £2m | -0.1% | |
TRLSTrellus Health plc | £516k | -0.9% |